The complex product portfolio developed over the years, the annual launch of new medicines, the manufacture of leading-edge modified-release and fixed combination pharmaceuticals, and the continuous R&D and pharmaceutical manufacturing activities meet the particular needs of patients worldwide for modern and effective treatments. Through its production plant in Targu Mures, Gedeon Richter Romania is meeting all these objectives by producing more than 60 medicines in approximately 300 dosage forms. Our products are designed to offer effective and modern treatment options at affordable prices to all categories of customers. The most important of these medicines are for the treatment of cardiovascular, central nervous system, respiratory and urinary tract disorders and are marketed as tablets, capsules, ointments, solutions, suspensions, or syrups.
As a result of the development of recent years, the Dorog plants have become fundamental to ensuring the supply of active ingredients for our Women's Healthcare portfolio. Two steroid plants with a high level of steroid chemistry knowledge, manufacturing experience and a special technical base serve the needs of our gynecological strategic pillar with an ever-widening product range.
The API for one of our best-known products, Panangin, is also manufactured in Dorog, as well as most of our generic portfolio and our prorietary antipsychotic.
With a headcount of 740 employees, Gedeon Richter Polska is engaged in the manufacturing of finished dosage drugs and solid form packaging (tablet, capsule). The product portfolio comprises gastrointestinal, cardiovascular and anti-inflammatory preparations. Polfa markets 32 brands in several presentations in Poland. Its major export markets are Russia, Belarus, Uzbekistan, Romania and the Ukraine.
Similar to the parent company, GR Polska is also involved in marketing, promotion and R&D as well.